1-3 of 3
Daisuke Morishita, PhD
Close
Sort by
Journal Articles

CARD11 Mutation Induces Oligoclonal Expansion of T-Cells, and Accelerates ATL Development in Combination with HBZ

Takuro Kameda, MD PhD, Kotaro Shide, MD PhD, Ayako Kamiunten, MD, Tahira Yuki, Masaaki Sekine, MD, Keiichi Akizuki, MD, Tomonori Hidaka, MD, Yoko Kubuki, MD PhD, Midori Sugiyama, Daisuke Morishita, PhD, Kazuya Shimoda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–18.
https://doi.org/10.1182/blood-2020-142242
Published: 2020
Journal Articles

Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

Daisuke Morishita, PhD, Akio Mizutani, PhD, Hirokazu Tozaki, PhD, Yasuyoshi Arikawa, PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Keisuke Kataoka, MD PhD, Akinori Yoda, PhD, Yotaro Ochi, MD, Kotaro Shide, MD PhD, Koji Izutsu, MD PhD, Yosuke Minami, MDPhD, Kazuya Shimoda, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-141824
Published: 2020
Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, PhD, Daisuke Morishita, PhD, Akio Mizutani, PhD, Yoshihiko Satoh, PhD, Yotaro Ochi, MD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 404.
https://doi.org/10.1182/blood-2019-131559
Published: 2019